The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
Open accessAbstract
The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-ERK signal cascade, functions to transmit upstream signals to its downstream effectors to regulate physiological process such as cell proliferation, differentiation, survival and death. As the most frequently mutated signaling pathway in human cancer, targeting the MAPK pathway has long been considered a promising strategy for cancer therapy. Substantial efforts in the past decades have led to the clinical success of BRAF and MEK inhibitors. However, the clinical benefits of these inhibitors are compromised by the frequently occurring acquired resistance due to cancer heterogeneity and genomic instability. This review briefly introduces the key protein kinases involved in this pathway as well as their activation mechanisms. We also generalize the correlations between mutations of MAPK members and human cancers, followed by a summarization of progress made on the development of small molecule MAPK kinases inhibitors. In particular, this review highlights the potential advantages of ERK inhibitors in overcoming resistance to upstream targets and proposes that targeting ERK kinase may hold a promising prospect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
ERK implication in cell cycle regulation
Chambard, J.-C., Lefloch, R., Pouysségur, J., & Lenormand, P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.010 · Cited by 750
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 585
Mixed-lineage kinase control of JNK and p38 MAPK pathways
Gallo, K. A., & Johnson, G. L. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm906 · Cited by 572
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
The ins and outs of Raf kinases
Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J., & Rapp, U. R. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90133-3 · Cited by 524
Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., & Okumura, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3537 · Cited by 517
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells
Ramos, J. W. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.009 · Cited by 474
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
MAPK signalling: ERK5 versus ERK1/2
Nishimoto, S., & Nishida, E. (2006) · EMBO reports · doi:10.1038/sj.embor.7400755 · Cited by 432
Signaling Interplay in Ras Superfamily Function
Mitin, N., Rossman, K. L., & Der, C. J. (2005) · Current Biology · doi:10.1016/j.cub.2005.07.010 · Cited by 399
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Zhao, Q., & Lee, F. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8355 · Cited by 274
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras-Raballand, A., de Mestier, L., Cros, J., Faivre, S., & Raymond, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 264
The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier
Sturm, O. E., Orton, R., Grindlay, J., Birtwistle, M., Vyshemirsky, V., Gilbert, D., Calder, M., Pitt, A., Kholodenko, B., & Kolch, W. (2010) · Science Signaling · doi:10.1126/scisignal.2001212 · Cited by 247
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0185 · Cited by 221
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 211
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199
Trametinib: a MEK inhibitor for management of metastatic melanoma
Rutkowski, P., Lugowska, I., Kosela-Paterczyk, H., & Kozak, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72951 · Cited by 171
Blake, J. F., Burkard, M., Chan, J., Chen, H., Chou, K.-J., Diaz, D., Dudley, D. A., Gaudino, J. J., Gould, S. E., Grina, J. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00389 · Cited by 159
Aronov, A. M., Tang, Q., Martínez-Botella, G., Bemis, G. W., Cao, J., Chen, G., Ewing, N. P., Ford, P. J., Germann, U. A., Green, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900630q · Cited by 152
Eblen, S. T., Slack‐Davis, J. K., Tarcsafalvi, A., Parsons, J. T., Weber, M. J., & Catling, A. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2308-2317.2004 · Cited by 148
Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K. H., Ong, M., Banerji, U., Papadimitrakopoulou, V. A., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 141
MAP3Ks as central regulators of cell fate during development
Craig, E. A., Stevens, M. V., Vaillancourt, R. R., & Camenisch, T. D. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21750 · Cited by 132
Sánchez‐Laorden, B. L., Virós, A., Girotti, M. R., Pedersen, M., Saturno, G., Zambon, A., Niculescu‐Duvaz, D., Turajlic, S., Hayes, A. J., Gore, M. E., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004815 · Cited by 131
Ledford, H. K. (2015) · Nature · doi:10.1038/520278a · Cited by 126
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Carlino, M. S., Todd, J. R., Gowrishankar, K., Mijatov, B., Pupo, G. M., Fung, C., Snoyman, S., Hersey, P., Long, G. V., Kefford, R. F., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.01.003 · Cited by 120
Johnson, G. L., Dohlman, H. G., & Graves, L. M. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.004 · Cited by 119
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 113
Interactions between Ras and Raf: Key regulatory proteins in cellular transformation
Marshall, M. S. (1995) · Molecular Reproduction and Development · doi:10.1002/mrd.1080420418 · Cited by 108
K-Ras protein as a drug target
McCormick, F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1382-7 · Cited by 105
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
Manousaridis, I., Mavridou, S., Goerdt, S., Leverkus, M., & Utikal, J. S. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04546.x · Cited by 99
Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
Estep, A. L., Palmer, C., McCormick, F. P., & Rauen, K. A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001279 · Cited by 94
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Marusiak, A. A., Edwards, Z. C., Hugo, W., Trotter, E. W., Girotti, M. R., Stephenson, N. L., Kong, X., Gartside, M. G., Fawdar, S., Hudson, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4901 · Cited by 86
Lloyd, A. C. (2006) · Journal of Biology · doi:10.1186/jbiol46 · Cited by 84
Inhibitors of Ras–SOS Interactions
Lu, S., Jang, H., Zhang, J., & Nussinov, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500481 · Cited by 72
ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15
Vaidyanathan, H., Opoku‐Ansah, J., Pastorino, S., Renganathan, H., Matter, M. L., & Ramos, J. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704514104 · Cited by 70
Dissecting Therapeutic Resistance to ERK Inhibition
Jha, S. S., Morris, E. J., Hruza, A. W., Mansueto, M. S., Schroeder, G. K., Arbanas, J. M., McMasters, D. R., Restaino, C. R., Dayananth, P., Black, S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0172 · Cited by 56
MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy
Zhang, X., Ma, L., Qi, J., Shan, H., Yu, W., & Gu, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2542-8 · Cited by 53
Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 52
Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 45
Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
Ren, L. M., Grina, J. A., Moreno, D., Blake, J. F., Gaudino, J. J., Garrey, R., Metcalf, A. T., Burkard, M., Martinson, M. C., Rasor, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501921k · Cited by 45
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Sabbatino, F., Wang, Y., Scognamiglio, G., Favoino, E., Feldman, S. A., Villani, V., Flaherty, K. T., Nota, S. P. F. T., Giannarelli, D., Simeone, E., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv435 · Cited by 42
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
Robinson, J. P., VanBrocklin, M. W., Lastwika, K. J., McKinney, A. J., Brandner, S., & Holmen, S. L. (2010) · Oncogene · doi:10.1038/onc.2010.513 · Cited by 38
Germann, U. A., Furey, B. F., Roix, J. J., Markland, W., Hoover, R. R., Aronov, A. M., Hale, M. R., Chen, G., Martínez-Botella, G., Alargova, R. G., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-4693 · Cited by 22
Wong, D. J. L., Robert, L., Atefi, M. S., Lassen, A., Avarappatt, G., Cerniglia, M., Avramis, E. V., Tsoi, J., Foulad, D. S., Graeber, T. G., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0393-2 · Cited by 13
Cited by
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 348
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Gao, W., Wang, C., Yu, L., Sheng, T., Wu, Z., Wang, X., Zhang, D., Lin, Y., & Gong, Y. (2019) · BioMed Research International · doi:10.1155/2019/6769789 · Cited by 220
Metadata
- Authors
- Liu, F., Yang, X., Geng, M., & Huang, M.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 8
- Issue
- 4
- Pages
- 552-562
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2793589490
- Cited by
- 432
- References
- 77
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.